190 related articles for article (PubMed ID: 12426058)
21. Commentary on "Alpha-synuclein and mitochondria: a tangled skein".
Beal MF
Exp Neurol; 2004 Apr; 186(2):109-11. PubMed ID: 15026249
[No Abstract] [Full Text] [Related]
22. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Przedborski S; Chen Q; Vila M; Giasson BI; Djaldatti R; Vukosavic S; Souza JM; Jackson-Lewis V; Lee VM; Ischiropoulos H
J Neurochem; 2001 Jan; 76(2):637-40. PubMed ID: 11208927
[TBL] [Abstract][Full Text] [Related]
23. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells.
Fornai F; Lenzi P; Gesi M; Soldani P; Ferrucci M; Lazzeri G; Capobianco L; Battaglia G; De Blasi A; Nicoletti F; Paparelli A
J Neurochem; 2004 Jan; 88(1):114-23. PubMed ID: 14675155
[TBL] [Abstract][Full Text] [Related]
24. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
26. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.
Hishikawa N; Niwa J; Doyu M; Ito T; Ishigaki S; Hashizume Y; Sobue G
Am J Pathol; 2003 Aug; 163(2):609-19. PubMed ID: 12875980
[TBL] [Abstract][Full Text] [Related]
27. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein.
Rockenstein E; Schwach G; Ingolic E; Adame A; Crews L; Mante M; Pfragner R; Schreiner E; Windisch M; Masliah E
J Neurosci Res; 2005 Apr; 80(2):247-59. PubMed ID: 15765523
[TBL] [Abstract][Full Text] [Related]
28. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
Giasson BI; Duda JE; Quinn SM; Zhang B; Trojanowski JQ; Lee VM
Neuron; 2002 May; 34(4):521-33. PubMed ID: 12062037
[TBL] [Abstract][Full Text] [Related]
29. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
Norris EH; Giasson BI
Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
[TBL] [Abstract][Full Text] [Related]
30. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
Masliah E; Rockenstein E; Adame A; Alford M; Crews L; Hashimoto M; Seubert P; Lee M; Goldstein J; Chilcote T; Games D; Schenk D
Neuron; 2005 Jun; 46(6):857-68. PubMed ID: 15953415
[TBL] [Abstract][Full Text] [Related]
31. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
32. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
33. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitin-proteasome system and Parkinson's diseases.
Betarbet R; Sherer TB; Greenamyre JT
Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
[TBL] [Abstract][Full Text] [Related]
35. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions.
Tsuchiya K; Tajima H; Kuwae T; Takeshima T; Nakano T; Tanaka M; Sunaga K; Fukuhara Y; Nakashima K; Ohama E; Mochizuki H; Mizuno Y; Katsube N; Ishitani R
Eur J Neurosci; 2005 Jan; 21(2):317-26. PubMed ID: 15673432
[TBL] [Abstract][Full Text] [Related]
36. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Ren Q; Ma M; Yang J; Nonaka R; Yamaguchi A; Ishikawa KI; Kobayashi K; Murayama S; Hwang SH; Saiki S; Akamatsu W; Hattori N; Hammock BD; Hashimoto K
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5815-E5823. PubMed ID: 29735655
[TBL] [Abstract][Full Text] [Related]
37. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
38. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
[TBL] [Abstract][Full Text] [Related]
39. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation.
Thomas B; Mandir AS; West N; Liu Y; Andrabi SA; Stirling W; Dawson VL; Dawson TM; Lee MK
PLoS One; 2011 Jan; 6(1):e16706. PubMed ID: 21304957
[TBL] [Abstract][Full Text] [Related]
40. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
Haywood AF; Staveley BE
BMC Neurosci; 2004 Apr; 5():14. PubMed ID: 15090075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
